<DOC>
	<DOCNO>NCT01489059</DOCNO>
	<brief_summary>The purpose study determine whether combination interleukin-21 ( IL-21 ) Ipilimumab subject melanoma safe , provide preliminary information clinical benefit combination compare Ipilimumab alone</brief_summary>
	<brief_title>Safety Study IL-21/Ipilimumab Combination Treatment Melanoma</brief_title>
	<detailed_description>Allocation : Part 1 Dose Escalation Phase : Non-randomized ; Part 2 Cohort Expansion Phase : Randomized</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Unresectable Stage III Stage IV melanoma Part 1 Dose Escalation : Prior melanoma treatment allow except follow : ipilimumab , BMS982470 ( rIL21 ) , antiProgrammed Death1 ( antiPD1 ) , antiprogrammed deathligand 1 ( antiPDL1 ) , antiPDL2 antiCD137 Part 2 Cohort expansion : Prior treatment melanoma allow , except adjuvant therapy interferon alpha melanoma vaccine permit Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Measurable disease compute tomography ( CT ) magnetic resonance imaging ( MRI ) Normal liver function test Part 1 Dose escalation : subject ≤ 2 brain metastasis stable size , ≥ 4 week postradiation treatment , steroid allow Part 2 Cohort expansion : subject know suspected brain metastasis uveal melanoma exclude Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>